Annovis Bio Regains NYSE Listing Compliance
Annovis Bio (NYSE: ANVS) said the NYSE has confirmed it regained full compliance with continued listing standards. The NYSE notified the company on March 26, 2025 for failing Section 802.01B after average market cap and stockholders’ equity fell below $50 million for 30 days. Annovis’ plan was accepted June 19, 2025 with an 18-month cure period; compliance was restored within 12 months.
How this was made
The 30-second read
Why it matters
By confirming full compliance after corrective actions and quarterly updates, Annovis removes delisting risk while reiterating focus on pivotal Phase 3 AD topline data and regulatory submissions.
Market read
This is a risk-reduction catalyst for ANVS, but it does not replace clinical efficacy/safety catalysts that typically drive valuation.
What to watch
Market cap/equity thresholds can be volatile for clinical-stage firms; future financing or dilution could reintroduce compliance risk if not managed.
Background
NYSE notified Annovis in March 2025 for failing Section 802.01B thresholds; NYSE accepted a plan with an 18-month cure period starting from the original notice.
Ticker impact
Annovis regained NYSE continued-listing compliance after restoring market cap and stockholders’ equity above required thresholds.
Near-term upside bias from lower headline risk; magnitude likely limited versus clinical readouts.
The news is a compliance status update (not efficacy/safety), but it removes a binary market-structure risk that can pressure liquidity and investor participation.
Market effects
Highlights ongoing NYSE listing pressure for small-cap biotechs and the importance of maintaining market-cap/equity thresholds.
Primarily affects US-listed small-cap biotech liquidity and sentiment; limited broader regional spillover.
Low; compliance mechanics are NYSE-specific with minimal direct global read-across.
Counterpoint
Compliance relief may be largely technical; investors may refocus quickly on Phase 3 AD topline results and regulatory timelines.
Key entities
- issuerAnnovis Bio, Inc.
Phase 3 clinical-stage biotech developing buntanetap for neurodegenerative diseases; regained NYSE listing compliance.
- regulator/venueNew York Stock Exchange (NYSE)
Confirmed Annovis regained full compliance with continued listing requirements under Section 802.01B.
